growth stocks

US Treasury yields have climbed into the 5% range amid simultaneous interest rate hikes by the US and Japan — the first American hike in three years and two months. Commentators are watching how higher yields and a firmer yen ripple through growth stocks, with the FANG+ and NASDAQ 100 indices seen as most exposed to the shifting rate environment.

Investors are watching Dow Jones futures as Donald Trump's comments on Iran add uncertainty to markets at the start of trading. Attention is also on growth stocks with Micron, SpaceX and Tesla all nearing technical buy points, giving traders potential entry opportunities if broader market conditions hold and geopolitical tensions don't unsettle sentiment.

Spotify Technology is facing a renewed valuation test as investors weigh whether its expansion beyond music into podcasts and audiobooks can justify its stock price. The shift toward spoken-word content and subscription add-ons is increasingly central to the company's growth story, and market watchers are debating whether these newer businesses can sustain the premium the market has placed on SPOT shares.

Amazon is expanding its investments in India and robotics, according to financial commentary examining what the moves could mean for the company's stock. Analysts are weighing how increased spending on emerging markets and automation might affect Amazon's growth prospects, operating costs, and long-term valuation as investors assess the company's next phase.

US stocks have continued climbing even as bond yields surge, a divergence that has caught investors' attention. The Wall Street Journal examined past episodes of rising yields alongside strong equity markets, finding that such periods often end badly, with stocks eventually correcting as borrowing costs weigh on valuations and economic growth.

Amazon shares rose in premarket trading on Thursday ahead of the company's quarterly results, due after the close. Investors are watching for growth in the AWS cloud division and for guidance on capital expenditure, particularly spending tied to artificial intelligence infrastructure, which has become a key driver of sentiment around the stock this year.

Darden Restaurants, the parent company of Olive Garden, reports quarterly earnings on September 24, with investors watching whether the chain's recent growth can continue. Analysts are focused on same-store sales and guidance as casual dining demand shows mixed signals. The upcoming report is seen as a key test for the stock's near-term direction.

Apple's launch of a foldable iPhone is prompting investors to reassess the bull case for the company's stock. Commentary from analysts and market writers is focused on whether the new device category can reignite iPhone growth and justify bullish price targets for AAPL, as Apple looks for fresh revenue drivers in a maturing smartphone market.

Broadcom's stock is trading at roughly the same level where it ended 2025, even though the company's earnings have grown about 43% since then. The Motley Fool asks whether the flat share price makes the AI-chip and networking giant a buy, arguing that significantly higher earnings at the same valuation could signal upside. Investors are weighing whether Broadcom's recent stagnation reflects market caution or a buying opportunity.

Barron's reports that Apple is weighing a bigger push into the fast-growing fitness tracker market, and analysts are assessing what that could mean for AAPL stock. The segment is expanding quickly as consumers add wearables to their health routines, and investors are watching whether a deeper move could add a new growth driver for the company.

Microsoft shares are holding steady while US-Iran geopolitical tensions rattle broader markets, with retail investors calling MSFT the 'safest earnings play' ahead of its quarterly report. Traders argue the company's cloud and AI-driven growth makes it a defensive bet even in volatile conditions, though any escalation in the Middle East could still shift sentiment quickly.

Hims & Hers Health, the telehealth company known for prescription and wellness products, is trading at a low valuation while questions mount over the durability of its sales. Analysts and investors are debating whether the stock's cheap price reflects genuine risk to revenue growth, particularly around its popular weight-loss and telehealth offerings, or a buying opportunity.